INSPInspire Medical Systems, Inc.

NYSE inspiresleep.com


$ 192.01 $ 1.74 (0.91 %)    

Monday, 26-Aug-2024 10:08:11 EDT
QQQ $ 476.77 $ -3.16 (-0.66 %)
DIA $ 413.93 $ 1.08 (0.26 %)
SPY $ 562.12 $ -1.07 (-0.19 %)
TLT $ 98.26 $ -0.39 (-0.4 %)
GLD $ 232.68 $ -0.80 (-0.34 %)
$ 191.48
$ 190.27
$ 191.33 x 100
-- x --
$ 190.27 - $ 193.04
$ 123.00 - $ 257.40
312,380
na
5.71B
$ 1.68
$ 949.97
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-09-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-02-2023 03-31-2023 10-Q
7 02-10-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-02-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-15-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-02-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 06-07-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 keybanc-maintains-overweight-on-inspire-medical-systems-lowers-price-target-to-236

Keybanc analyst Brett Fishbin maintains Inspire Medical Systems (NYSE:INSP) with a Overweight and lowers the price target fr...

 rbc-capital-reiterates-outperform-on-inspire-medical-systems-maintains-260-price-target

RBC Capital analyst Shagun Singh reiterates Inspire Medical Systems (NYSE:INSP) with a Outperform and maintains $260 price t...

 baird-maintains-outperform-on-inspire-medical-systems-lowers-price-target-to-200

Baird analyst Mike Polark maintains Inspire Medical Systems (NYSE:INSP) with a Outperform and lowers the price target from $...

 inspire-medical-systems-q2-2024-adj-eps-032-may-not-compare-to-015-estimate-sales-19590m-beat-18625m-estimate

Inspire Medical Systems (NYSE:INSP) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of...

 inspire-medical-systems-expects-fy24-revenue-of-788m-798m-prior-775m-785m-vs-7879m-est

Updated Full Year 2024 Revenue Guidance Revenue for full year 2024 is anticipated to be in the range of $788 million to $798...

 inspire-medical-systems-announces-preliminary-q2-revenue-of-1959m-vs-1863m-est

Preliminary, Unaudited Second Quarter Revenue Revenue for the second quarter is anticipated to be $195.9 million, a 30% incr...

 inspire-medical-systems-announces-ce-mark-certification-under-european-unions-medical-device-regulation-for-inspire-therapy

"Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with un...

 truist-securities-maintains-buy-on-inspire-medical-systems-lowers-price-target-to-217

Truist Securities analyst Richard Newitter maintains Inspire Medical Systems (NYSE:INSP) with a Buy and lowers the price tar...

 morgan-stanley-maintains-overweight-on-inspire-medical-systems-lowers-price-target-to-210

Morgan Stanley analyst Kallum Titchmarsh maintains Inspire Medical Systems (NYSE:INSP) with a Overweight and lowers the pric...

 fda-labels-inspire-medicals-sleep-apnea-nerve-stimulator-recall-as-most-serious

Inspire Medical Systems recalls Model 3028 IPG due to manufacturing defect causing serious health risks. Learn about the FDA Cl...

 us-fda-says-inspire-medical-systems-removes-inspire-iv-implantable-pulse-generator-due-to-manufacturing-defect-that-can-result-in-system-malfunctions-fda-says-recall-as-the-most-serious-type

- Reuters

 stifel-maintains-hold-on-inspire-medical-systems-lowers-price-target-to-170

Stifel analyst Jonathan Block maintains Inspire Medical Systems (NYSE:INSP) with a Hold and lowers the price target from $21...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION